UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2021

Commission File Number 000-20181

 

SAPIENS INTERNATIONAL CORPORATION N.V.

(Translation of Registrant’s name into English)

 

Azrieli Center

26 Harokmim St.

Holon, 5885800

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒            Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

 

 

 

CONTENTS

 

Exhibit No.   Title of Exhibit
99.1   Press Release

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  

  Sapiens International Corporation N.V.
   
  By:  /s/ Roni Giladi
  Name:  Roni Giladi
  Title: Chief Financial Officer

 

Dated: May 4, 2021

 

2

 

 

EXHIBIT INDEX

 

The following exhibits are furnished as part of this Form 6-K:

 

Exhibit No.   Title of Exhibit
99.1   Press Release

 

 

3

 

 

Exhibit 99.1

 

 

 

Sapiens Reports First Quarter 2021 Financial Results

 

Holon, Israel, May 4, 2021Sapiens International Corporation, (NASDAQ and TASE: SPNS), a leading global provider of software solutions for the insurance industry, today announced its financial results for the first quarter ended March 31, 2021.

 

Summary Results for First Quarter 2021 (USD in millions, except per share data)

 

    GAAP           Non-GAAP        
    Q1 2021     Q1 2020     % Change     Q1 2021     Q1 2020     % Change  
Revenue   $ 109.6     $ 90.5       21.1 %   $ 110.2     $ 90.5       21.7 %
Gross Profit   $ 44.3     $ 36.3       22.0 %   $ 49.2     $ 39.8       23.7 %
Gross Margin     40.4 %     40.1 %     30 bps     44.7 %     44.0 %     70 bps
Operating Income   $ 12.4     $ 10.3       20.3 %   $ 19.0     $ 14.6       30.0 %
Operating Margin     11.3 %     11.4 %     (10 )bps     17.2 %     16.1 %     110 bps
Net Income (*)   $ 9.8     $ 6.8       44.2 %   $ 14.9     $ 10.4       43.2 %
Diluted EPS   $ 0.18     $ 0.13       38.5 %   $ 0.27     $ 0.20       35.0 %

 

(*) Attributable to Sapiens’ shareholders.

 

“Our revenue growth in the first quarter validates our strategy of building global diversity with a broad business portfolio, which provides the foundation for Sapiens’ performance and growth. Solid execution in the first quarter delivered 22% non-GAAP revenue growth, with non-GAAP revenues reaching a record $110 million and non-GAAP operating margin increasing to 17.2% from 16.1%. Our growth in the first quarter originated primarily from Europe and Rest-of-the-World. Operating a global company across multiple insurance markets and deploying a diversified product offering allows us to balance our growth, resources, investments, and risks across regions and markets. With a strategic focus and the increasing global market demand for digital insurance solutions and transformations, Sapiens is well positioned for continued financial performance,” said Roni Al-Dor, Sapiens president and CEO.

 

“We are increasing our 2021 revenue guidance to a range of $459 to $464 million from our prior range of $457 to $463 million. We are also updating our operating profit margin guidance, due to our plan initiated this quarter to manage our growth and investment in delivery capabilities in the North American P&C CoreSuite business, and following the recent spike in COVID-19 in India, which will increase our labor costs in the short term. As a result of these two factors, operating margin in 2021 is expected to be in the range of 17.0% to 17.4% compared to the previous range of 17.7% to 18.0%. I would like to highlight that Sapiens remains committed to increasing its profitability and margins, as we have done year after year.”

 

Quarterly Results Conference Call

 

Management will host a conference call and webcast today, May 4, 2021 at 9:30 a.m. Eastern Time (4:30 p.m. in Israel) to review and discuss Sapiens’ results.

 

Please call the following numbers (at least 10 minutes before the scheduled time) to participate:

North America (toll-free): + 1-888- 642-5032; International: +972-3-918-0609; UK: 0-800-917-5108.

 

The live webcast of the call can be accessed on Sapiens’ website at https://www.sapiens.com/investor-relations/ir-events-presentations/. A replay of the call will be available one business day following the completion of the event at the same location for 90 days.

 

1

 

 

Non-GAAP Financial Measures

 

This press release contains the following non-GAAP financial measures: non-GAAP revenue, non-GAAP gross profit, non-GAAP operating income, non-GAAP net income attributed to Sapiens shareholders, non-GAAP basic and diluted earnings per share, Adjusted EBITDA and Adjusted Free Cash-Flow.

 

Sapiens believes that these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to Sapiens’ financial condition and results of operations. The Company’s management uses these non-GAAP measures to compare the Company’s performance to that of prior periods for trend analyses, for purposes of determining executive and senior management incentive compensation and for budgeting and planning purposes. These measures are used in financial reports prepared for management and in quarterly financial reports presented to the Company’s board of directors. The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends, and in comparing the Company’s financial measures with other software companies, many of which present similar non-GAAP financial measures to investors.

 

Non-GAAP financial measures consist of GAAP financial measures adjusted to exclude: Valuation adjustment on acquired deferred revenue, amortization of capitalized software development and other intangible assets, capitalization of software development, stock-based compensation, compensation related to acquisition and acquisition-related costs, restructuring and cost reduction costs, and tax adjustments related to non-GAAP adjustments.

 

Management of the Company does not consider these non-GAAP measures in isolation, or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements. In addition, they are subject to inherent limitations, as they reflect the exercise of judgment by management about which expenses and income are excluded or included in determining these non-GAAP financial measures.

 

To compensate for these limitations, management presents non-GAAP financial measures in connection with GAAP results. Sapiens urges investors to review the reconciliation of its non-GAAP financial measures to the comparable GAAP financial measures, which it includes in press releases announcing quarterly financial results, including this press release, and not to rely on any single financial measure to evaluate the Company’s business.

 

2

 

 

Reconciliation tables of the most comparable GAAP financial measures to the non-GAAP financial measures used in this press release are included with the financial tables of this release.

 

The Company defines Adjusted EBITDA as net profit, adjusted for valuation adjustment on acquired deferred revenue, stock-based compensation expense, depreciation and amortization, capitalized of software development costs, compensation expenses related to acquisition and acquisition-related costs, restructuring and cost reduction costs, financial expense (income), provision for income taxes and other income (expenses). These amounts are often excluded by other companies to help investors understand the operational performance of their business.

 

The Company uses Adjusted EBITDA as a measurement of its operating performance, because it assists in comparing the operating performance on a consistent basis by removing the impact of certain non-cash and non-operating items. Adjusted EBITDA reflects an additional way of viewing aspects of the operations that the Company believes, when viewed with the GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provide a more complete understanding of factors and trends affecting its business. The Company uses Adjusted Free Cash-Flow as a measurement of its operating performance, and reconciles cash-flow from operating activities to Adjusted Free Cash-Flow, while reducing the amounts for capitalization of software development costs and capital expenditures. The Company adds back cash payments made for former acquisitions in respect of  future performance targets and retention criteria as determined upon acquisition date of the respective acquired company, which were included in the cash-flow from operating activities. We believe that Adjusted Free Cash-Flow is useful in evaluating our business, because Adjusted Free Cash-Flow reflects the cash surplus available to fund the expansion of our business.

 

About Sapiens

 

Sapiens International Corporation empowers insurers to succeed in an evolving industry. The company offers digital software platforms, solutions and services for the property and casualty, life, pension and annuity, reinsurance, financial and compliance, workers’ compensation and financial markets. With more than 35 years of experience delivering to more than 600 organizations globally, Sapiens has a proven ability to satisfy customers’ core, data and digital requirements. For more information: www.sapiens.com.

 

3

 

 

Forward Looking Statements

 

Certain matters discussed in this press release that are incorporated herein and therein by reference are forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that are based on our beliefs, assumptions and expectations, as well as information currently available to us. Such forward-looking statements may be identified by the use of the words “anticipate,” “believe,” “estimate,” “expect,” “may,” “will,” “plan” and similar expressions. Such statements reflect our current views with respect to future events and are subject to certain risks and uncertainties. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: the COVID-19 (coronavirus) pandemic, which may last longer than expected and materially adversely affect our results of operations; the degree of our success in our plans to leverage our global footprint to grow our sales; the degree of our success in integrating the companies that we have acquired through the implementation of our M&A growth strategy; the lengthy development cycles for our solutions, which may frustrate our ability to realize revenues and/or profits from our potential new solutions; our lengthy and complex sales cycles, which do not always result in the realization of revenues; the degree of our success in retaining our existing customers or competing effectively for greater market share; difficulties in successfully planning and managing changes in the size of our operations; the frequency of the long-term, large, complex projects that we perform that involve complex estimates of project costs and profit margins, which sometimes change mid-stream; the challenges and potential liability that heightened privacy laws and regulations pose to our business; occasional disputes with clients, which may adversely impact our results of operations and our reputation; various intellectual property issues related to our business; potential unanticipated product vulnerabilities or cybersecurity breaches of our or our customers’ systems; risks related to the insurance industry in which our clients operate; risks associated with our global sales and operations, such as changes in regulatory requirements, wide-spread viruses and epidemics like the recent novel coronavirus outbreak, or fluctuations in currency exchange rates; and risks related to our principal location in Israel and our status as a Cayman Islands company.

 

While we believe such forward-looking statements are based on reasonable assumptions, should one or more of the underlying assumptions prove incorrect, or these risks or uncertainties materialize, our actual results may differ materially from those expressed or implied by the forward-looking statements. Please read the risks discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F, in order to review conditions that we believe could cause actual results to differ materially from those contemplated by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, to conform these statements to actual results or to changes in our expectations.

 

Investors and Media Contact

Sapiens

Daphna Golden

Vice President, Head of Investor Relations

Email: ir@sapiens.com

4

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

U.S. dollars in thousands (except per share amounts)

 

    Three months ended  
    March 31,  
    2021     2020  
    (unaudited)     (unaudited)  
             
Revenue     109,592       90,534  
Cost of revenue     65,336       54,270  
                 
Gross profit     44,256       36,264  
                 
Operating expenses:                
Research and development, net     13,088       10,526  
Selling, marketing, general and administrative     18,803       15,460  
Total operating expenses     31,891       25,986  
                 
Operating income     12,365       10,278  
                 
Financial and other expenses, net     515       1,487  
Taxes on income     1,948       1,901  
                 
Net income     9,902       6,890  
                 
Attributed to non-controlling interest     67       70  
                 
Net income attributable to Sapiens’ shareholders     9,835       6,820  
Basic earnings per share     0.18       0.14  
                 
Diluted earnings per share     0.18       0.13  
                 
Weighted average number of shares outstanding used to compute basic earnings per share (in thousands)     54,689       50,175  
                 
Weighted average number of shares outstanding used to compute diluted earnings per share (in thousands)     55,567       51,083  

 

5

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED NON-GAAP STATEMENTS OF INCOME

U.S. dollars in thousands (except per share amounts)

 

    Three months ended  
    March 31,  
    2021     2020  
    (unaudited)     (unaudited)  
             
Revenue     110,222       90,534  
Cost of revenue     60,993       50,743  
                 
Gross profit     49,229       39,791  
                 
Operating expenses:                
Research and development, net     14,720       11,963  
Selling, marketing, general and administrative     15,509       13,214  
Total operating expenses     30,229       25,177  
                 
Operating income     19,000       14,614  
                 
Financial and other expenses, net     515       1,487  
Taxes on income     3,510       2,645  
                 
Net income     14,975       10,482  
                 
Attributable to non-controlling interest     67       70  
                 
Net income attributable to Sapiens’ shareholders     14,908       10,412  
                 
Basic earnings per share     0.27       0.21  
                 
Diluted earnings per share     0.27       0.20  
                 
Weighted average number of shares outstanding used to compute basic earnings per share (in thousands)     54,689       50,175  
                 
Weighted average number of shares outstanding used to compute diluted earnings per share (in thousands)     55,567       51,083  

 

6

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND SUBSIDIARIES

 

RECONCILIATION OF GAAP TO NON-GAAP RESULTS

U.S. dollars in thousands (except per share amounts)

 

    Three months ended  
    March 31,  
    2021     2020  
    (unaudited)     (unaudited)  
             
GAAP revenue     109,592       90,534  
Valuation adjustment on acquired deferred revenue     630       -  
Non-GAAP revenue     110,222       90,534  
                 
GAAP gross profit     44,256       36,264  
Revenue adjustment     630       -  
Amortization of capitalized software     1,784       1,496  
Amortization of other intangible assets     2,559       2,031  
Non-GAAP gross profit     49,229       39,791  
                 
GAAP operating income     12,365       10,278  
Gross profit adjustments     4,973       3,527  
Capitalization of software development     (1,632 )     (1,437 )
Amortization of other intangible assets     1,366       589  
Stock-based compensation     1,399       622  
Acquisition-related costs *)     529       1,035  
Non-GAAP operating income     19,000       14,614  
                 
GAAP net income attributable to Sapiens’ shareholders     9,835       6,820  
Operating income adjustments     6,635       4,336  
Taxes on income     (1,562 )     (744 )
Non-GAAP net income attributable to Sapiens’   shareholders     14,908       10,412  

 

(*) Acquisition-related costs pertain to charges on behalf of M&A agreements related to future performance targets and retention criteria, as well as third-party services, such as, tax, accounting and legal rendered until the acquisition date.

7

 

 

Summary of NON-GAAP Financial Information
U.S. dollars in thousands (except per share amounts)

 

    Q1 2021     Q4 2020     Q3 2020     Q2 2020     Q1 2020  
                               
Revenues     110,222       102,936       97,968       93,063       90,534  
Gross profit     49,229       47,044       44,206       41,900       39,791  
Operating income     19,000       18,666       17,859       16,783       14,614  
Net income to Sapiens’ shareholders     14,908       14,461       13,746       13,340       10,412  
Adjusted EBITDA     20,120       20,032       19,010       17,854       15,724  
                                         
Basic earnings per share     0.27       0.27       0.27       0.27       0.21  
Diluted earnings per share     0.27       0.27       0.27       0.26       0.20  

 

Non-GAAP Revenues by Geographic Breakdown
U.S. dollars in thousands

 

    Q1 2021     Q4 2020     Q3 2020     Q2 2020     Q1 2020  
                               
North America     44,754       47,303       49,979       46,610       44,567  
Europe     57,642       49,225       42,394       41,030       40,232  
Rest of the world     7,826       6,408       5,595       5,423       5,735  
                                         
Total     110,222       102,936       97,968       93,063       90,534  

 

Adjusted Free Cash-Flow

U.S. dollars in thousands

 

    Q1 2021     Q4 2020     Q3 2020     Q2 2020     Q1 2020  
                               
Cash-flow from operating activities     11,755       21,030       16,705       14,761       5,759  
Increase in capitalized software development costs     (1,632 )     (1,604 )     (1,506 )     (1,251 )     (1,437 )
Capital expenditures     (821 )     (725 )     (963 )     (393 )     (552 )
Free cash-flow     9,302       18,701       14,236       13,117       3,770  
                                         
Cash payments attributed to acquisition-related costs(*) (**)     1,280       2,363       242       1,562       737  
                                         
Adjusted free cash-flow     10,582       21,064       14,478       14,679       4,507  

 

(*) Included in cash-flow from operating activities

 

(**) Acquisition-related payments pertain to payments on behalf of M&A agreements related to future performance targets and retention criteria, as well as third-party services, such as, tax, accounting and legal rendered until the acquisition date.

8

 

 

Adjusted EBITDA Calculation
U.S. dollars in thousands

 

    Three months ended  
    March 31,  
    2021     2020  
    (unaudited)     (unaudited)  
             
GAAP operating income     12,365       10,278  
                 
Non-GAAP adjustments:                
Valuation adjustment on acquired deferred revenue     630       -  
Amortization of capitalized software     1,784       1,496  
Amortization of other intangible assets     3,925       2,620  
Capitalization of software development     (1,632 )     (1,437 )
Stock-based compensation     1,399       622  
Compensation related to acquisition and acquisition-related costs     529       1,035  
                 
Non-GAAP operating income     19,000       14,614  
                 
Depreciation     1,120       1,110  
                 
Adjusted EBITDA     20,120       15,724  

 

9

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands

 

    March 31,     December 31,  
    2021     2020  
    (unaudited)     (unaudited)  
             
ASSETS            
             
CURRENT ASSETS            
Cash and cash equivalents     142,184       152,561  
Short-term bank deposit     30,000       30,000  
Trade receivables, net and unbilled receivables     74,762       65,409  
Other receivables and prepaid expenses     16,494       19,388  
                 
Total current assets     263,440       267,358  
                 
LONG-TERM ASSETS                
Property and equipment, net     16,585       16,970  
Severance pay fund     6,604       6,582  
Goodwill and intangible assets, net     352,130       363,597  
Operating lease right-of-use assets     51,716       54,390  
Other long-term assets     6,078       5,264  
                 
Total long-term assets     433,113       446,803  
                 
TOTAL ASSETS     696,553       714,161  
                 
LIABILITIES AND EQUITY                
                 
CURRENT LIABILITIES                
Trade payables     6,057       5,389  
Current maturities of Series B Debentures     19,796       19,796  
Accrued expenses and other liabilities     68,750       75,119  
Current maturities of operating lease liabilities     10,719       9,924  
Deferred revenue     41,470       34,548  
                 
Total current liabilities     146,792       144,776  
                 
LONG-TERM LIABILITIES                
Series B Debentures, net of current maturities     78,906       98,676  
Deferred tax liabilities     14,704       16,010  
Other long-term liabilities     13,037       12,129  
Long-term operating lease liabilities     46,531       48,773  
Redeemable non-controlling interest     562       517  
Accrued severance pay     9,530       9,586  
                 
Total long-term liabilities     163,270       185,691  
                 
EQUITY     386,491       383,694  
                 
TOTAL LIABILITIES AND EQUITY     696,553       714,161  

 

10

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONSOLIDATED STATEMENT OF CASH FLOW
U.S. dollars in thousands

 

    For the three months ended
March 31,
 
    2021     2020  
    (unaudited)     (unaudited)  
Cash flows from operating activities:            
Net income     9,902       6,890  
Reconciliation of net income to net cash provided by operating activities:                
Depreciation and amortization     6,829       5,226  
Accretion of discount on Series B Debentures     26       33  
Stock-based compensation related to options issued to employees     1,399       622  
Capital loss from sale of property and equipment     5       -  
                 
Net changes in operating assets and liabilities, net of amount acquired:                
Trade receivables, net and unbilled receivables     (10,541 )     (9,009 )
Deferred tax assets, net     (1,913 )     (1,257 )
Other operating assets     6,116       2,260  
Trade payables     609       (52 )
Other operating liabilities     (7,774 )     (759 )
Deferred revenues     6,995       1,655  
Accrued severance pay, net     102       150  
                 
Net cash provided by operating activities     11,755       5,759  
                 
Cash flows from investing activities:                
Purchase of property and equipment     (821 )     (552 )
Investment in deposit     -       (665 )
Proceeds from restricted deposit used for completed acquisition     -       22,890  
Payments for business acquisitions, net of cash acquired     -       (22,061 )
Proceeds from sale of property and equipment     154       -  
Capitalized software development costs     (1,632 )     (1,437 )
                 
Net cash used in investing activities     (2,299 )     (1,825 )
                 
Cash flows from financing activities:                
Proceeds from employee stock options exercised     413       600  
Repayment of Series B Debenture     (19,796 )     (9,898 )
Receipt of short-term loan     -       20,000  
Payment of contingent considerations     (537 )     (538 )
Dividend to non-controlling interest     (31 )     -  
                 
Net cash provided by (used in) financing activities     (19,951 )     10,164  
                 
Effect of exchange rate changes on cash and cash equivalents     118       (836 )
                 
Increase (decrease) in cash and cash equivalents     (10,377 )     13,262  
Cash and cash equivalents at the beginning of period     152,561       66,295  
                 
Cash and cash equivalents at the end of period     142,184       79,557  

 

11

 

 

Debentures Covenants

 

As of March 31, 2021, Sapiens was in compliance with all of its financial covenants under the indenture for the Series B Debentures, based on having achieved the following in its consolidated financial results:

 

Covenant 1

     
§ Target shareholders’ equity (excluding minority interest): above $120 million.
§ Actual shareholders’ equity (excluding minority interest) equal to $384 million.

 

Covenant 2

     
§ Target ratio of net financial indebtedness to net capitalization (in each case, as defined under the indenture for the Company’s Series B Debentures) below 65%.
§ Actual ratio of net financial indebtedness to net capitalization equal to (22.55)%.

 

Covenant 3

     
§ Target ratio of net financial indebtedness to EBITDA (accumulated calculation for the four last quarters) is below 5.5.
§ Actual ratio of net financial indebtedness to EBITDA (accumulated calculation for the four last quarters) is equal to (0.92).

 

12